Having licensed rights to Movantik from AstraZeneca in February, RedHill has now offloaded EU rights to Cosmo. Calliditas to obtain PBC candidate in bid to acquire Genkyotex.

It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.

US speciality drugs group will fund the $25m costs of the UK company's new Phase III trial of Lupuzor, which has been much maligned by analysts.

The UK biotech is expanding access to its unapproved lupus drug, has signed a licensing deal with Incantera and unveiled plans to divest its metabolic disorder subsidiary Ureka but fears about ImmuPharma's future remain.